JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 48:438-445, doi:10.1016/j.jacc.2006.04.070 (Published online 11 July 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (66)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cannon, C. P.
Right arrow Articles by Braunwald, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cannon, C. P.
Right arrow Articles by Braunwald, E.

Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy

Christopher P. Cannon, MD*, Benjamin A. Steinberg, BA, Sabina A. Murphy, MPH, Jessica L. Mega, MD and Eugene Braunwald, MD

Thrombolysis In Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts.


Figure 1
View larger version (18K):

[in a new window]
  		Figure 1 Low-density lipoprotein cholesterol (LDL-C) levels of trials comparing high-dose to standard-dose statin therapy. *Values for trials are estimated means, as not all individual LDL-C measurements were available.

 

Figure 2
View larger version (17K):

[in a new window]
  		Figure 2 Individual trials and pooled analysis showing a highly significant 16% reduction in the risk of coronary death or myocardial infarction (p < 0.0001). CI = confidence interval; OR = odds ratio.

 

Figure 3
View larger version (17K):

[in a new window]
  		Figure 3 Individual trials and pooled analysis showing a highly significant 16% reduction in the risk of coronary death or any cardiovascular event (myocardial infarction, stroke, hospitalization for unstable angina, or revascularization) (p < 0.0001). CI = confidence interval; OR = odds ratio.

 

Figure 4
View larger version (25K):

[in a new window]
  		Figure 4 Individual and pooled analyses showing non-significant trend in reduction of cardiovascular death (A), no increased risk of non-cardiovascular mortality (B), and a non-significant trend toward decreased overall mortality with high-dose statins (C). CI = confidence interval; OR = odds ratio.

 

Figure 5
View larger version (17K):

[in a new window]
  		Figure 5 Individual and pooled analyses demonstrating a significant 18% reduction of stroke with intensive statin therapy. CI = confidence interval; OR = odds ratio.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.